Everfront Biotech at BIO 2024: Competing in the Taiwan Smart Health GALA with 22 Startups

Date: June 3, 2024

The NSTC’s TTA held a pre-exhibition training camp to guide Taiwanese teams participating in the 2024 North American Biotech Exhibition. Photo/NSTC

On June 3 (U.S. time), the Taiwan Smart Health GALA, organized by the National Science and Technology Council (NSTC) and co-organized by ITRI and StartupIsland, will be grandly unveiled during the BIO 2024 International Convention. The event features distinguished speakers such as Peter Kurz, Chief Strategy Officer of Quantum International Corp (QIC), and Dr. Jau-Hua Lin, CEO of PharmaEssentia, who will share Taiwan’s formidable capabilities in biotech and pharmaceutical R&D.

Following the expert keynote speeches, Everfront Biotech, along with 22 other leading Taiwanese biotech companies and startups, will compete on the same stage. Dr. Jui-Hao Lee, Director of the Clinical Medicine Department, will present Everfront Biotech’s latest clinical trial results and breakthroughs in a two-minute presentation to the attendees.

The 22 companies span various fields including biopharmaceuticals, biotechnology, medical devices, and smart health, each showcasing their technology and progress in a two-minute presentation. These companies include: Anivance AI, CytoAurora Biotechnologies, ImmunAdd, Marker X, PrecisemAb, TaiYu, Acrocyte Therapeutics, CancerFree Biotech, CytoArm, Everfront Biotech Inc., JelloX Biotech, LumiSTAR Biotechnology, Pythia Biotech, Suntec Medical, Trust Bio-sonics, AB DigiHealth, AHEAD Intelligence, BioPro Scientific, Dot Space, iPreg, MoleculeX and FaceHeart.

News link: https://news.gbimonthly.com/tw/article/show.php?num=68303


Everfront Biotech Inc. cordially invites you to participate in the 2024 Taiwan Smart Health Gala

  • Topic: Taiwan Start Up Pitch
  • Date: June 3rd (Monday) 
  • Time: 10:15 – 11:35
  • Venue: Marriott Marquis San Diego Marina, Grand Ballroom B
Product Highlights of Cerebraca® Wafer:

Everfront Biotech’s innovative new drug, Cerebraca® Wafer, is a precision medicine sustained-release wafer that revolutionizes the treatment of malignant brain cancer. Through multiple patented novel features, Cerebraca® Wafer has successfully addressed the challenges of treating malignant brain cancer, which is difficult to manage and prone to relapse. Chemotherapy gradually loses its effectiveness against brain cancer cells due to their drug resistance, and the high proportion of cancer stem cells further exacerbates the problem of cancer recurrence and treatment resistance. However, these issues can be addressed by the pharmacological mechanism of action of Cerebraca® Wafer. In addition, malignant brain cancer cells express PD-L1, which renders the immune system unable to kill cancer cells. The successful development of Cerebraca® Wafer has also addressed this issue. In Phase I clinical trials, Cerebraca® Wafer has demonstrated efficacy without any drug-related adverse reactions. The median or average cumulative survival of relapsed malignant brain cancer patients has reached 25-26 months, which is significantly better than existing strategies such as Gliadel® wafer implantation (6.4 months), Temodal capsules (5.8 months), or Avastin injection (9.4 months). Cerebraca® Wafer has been approved by the Taiwan Ministry of Health and Welfare and the Human Research Ethics Committee of Hualien Tzu Chi Hospital for compassionate use trials. For malignant brain cancer patients who cannot undergo surgery and have tumors growing at the cervical spine, implanting Cerebraca® Wafer through a small incision has resulted in tumor shrinkage. In addition, combining Cerebraca® Wafer with cytokine-induced killer cells (CIK) for treatment can achieve a recurrence-free survival period of more than 40 months. With its outstanding clinical results, Everfront Biotech Inc. is actively seeking partners to jointly develop this new drug and help more malignant brain cancer patients.

Introduction to Everfront Biotech Inc.:

Everfront Biotech Inc. targets unmet medical needs by developing orphan drugs to treat some of the world’s most lethal diseases. Founded in 2010, the company focuses on the research and development of new drugs, emphasizing the screening of potential small molecules and advancing them to clinical trials. From initial product development to preclinical research, chemical manufacturing and control, new drug clinical trial applications, clinical trial planning, and execution, all these tasks are led by the company’s dedicated team.

Currently, Everfront has three clinical trials approved in the United States and Taiwan, including Cerebraca® Wafer (for malignant brain tumors)HK-001 (for amyotrophic lateral sclerosis), and EF-009 (for pancreatic cancer).

Everfront Biotech actively aligns with national new drug development policies. Both Cerebraca® Wafer and HK-001 have received biotech new drug certification. The company also actively participates in national projects, with three special projects and one SBIR project receiving funding from the Ministry of Economic Affairs. 

Development Pipeline